Algert Global LLC Boosts Holdings in Iovance Biotherapeutics, Inc. $IOVA

Key Points

• Algert Global increased its Iovance Biotherapeutics stake by 62.1% in the second quarter, adding 182,010 shares to own 474,939 shares valued at approximately $1.98 million. Institutional investors collectively own 77.03% of IOVA.
• Analyst sentiment is mixed but includes several target-price increases: TD Cowen raised its target to $10 with a Buy rating, while the consensus rating remains Hold with an average target of $8.89.
• Iovance exceeded quarterly expectations, reporting a loss of $0.11 per share versus the anticipated $0.13 loss and revenue of $198.63 million, up 65.7% year over year. However, analysts still expect continued losses, underscoring the importance of commercial execution and clinical progress.

Algert Global LLC raised its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) by 62.1% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 474,939 shares of the biotechnology company's stock after buying an additional 182,010 shares during the quarter. Algert Global LLC owned about 0.10% of Iovance Biotherapeutics worth $1,976,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of IOVA. Granite Investment Partners LLC acquired a new stake in shares of Iovance Biotherapeutics in the 4th quarter worth $29,000. Motley Fool Asset Management LLC acquired a new position in shares of Iovance Biotherapeutics during the fourth quarter worth about $29,000. M&T Bank Corp acquired a new position in shares of Iovance Biotherapeutics during the fourth quarter worth about $31,000. SBI Securities Co. Ltd. raised its holdings in Iovance Biotherapeutics by 169.1% during the fourth quarter. SBI Securities Co. Ltd. now owns 11,568 shares of the biotechnology company's stock worth $32,000 after purchasing an additional 7,269 shares in the last quarter. Finally, KBC Group NV purchased a new position in Iovance Biotherapeutics during the first quarter worth about $34,000. Hedge funds and other institutional investors own 77.03% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. TD Cowen upped their price objective on Iovance Biotherapeutics from $7.00 to $10.00 and gave the stock a "buy" rating in a report on Monday, August 24th. Robert W. Baird set a $6.00 target price on Iovance Biotherapeutics in a report on Friday, August 7th. UBS Group boosted their target price on shares of Iovance Biotherapeutics from $4.00 to $7.00 and gave the stock a "neutral" rating in a research report on Thursday, August 20th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Iovance Biotherapeutics in a research note on Thursday, July 2nd. Finally, Citizens Jmp increased their price target on shares of Iovance Biotherapeutics from $5.00 to $8.00 and gave the company a "market outperform" rating in a report on Friday, August 7th. Seven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, Iovance Biotherapeutics currently has an average rating of "Hold" and a consensus target price of $8.89.

Iovance Biotherapeutics Price Performance

IOVA opened at $8.01 on Friday. The stock has a market cap of $3.63 billion, a P/E ratio of -10.97 and a beta of 0.71. The stock's 50 day simple moving average is $5.47 and its 200 day simple moving average is $4.32. Iovance Biotherapeutics, Inc. has a 1-year low of $1.76 and a 1-year high of $9.36.

Iovance Biotherapeutics (NASDAQ:IOVA - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. The firm had revenue of $198.63 million during the quarter, compared to analysts' expectations of $87.83 million. Iovance Biotherapeutics had a negative return on equity of 40.51% and a negative net margin of 89.11%.Iovance Biotherapeutics's revenue was up 65.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.33) earnings per share. Research analysts expect that Iovance Biotherapeutics, Inc. will post -0.49 EPS for the current fiscal year.

Trending Headlines about Iovance Biotherapeutics

Here are the key news stories impacting Iovance Biotherapeutics this week:

• Positive Sentiment: Price target raised: Iovance’s price target was increased to $10.00, implying continued upside from recent trading levels and providing a potential catalyst for the stock. Iovance Biotherapeutics Price Target Raised to $10.00
• Positive Sentiment: Some earnings revisions improved: Zacks Research raised its Iovance EPS forecasts for the third quarter of 2026, full-year 2026, second quarter of 2027, second quarter of 2028 and full-year 2028. The FY2026 loss estimate improved from $0.62 to $0.56 per share, while the FY2028 loss estimate improved from $0.10 to $0.07, suggesting expectations for better profitability over time.
• Positive Sentiment: Sector interest: Iovance was highlighted among oncology companies benefiting from continued innovation in cancer treatments. The company’s focus on cell therapy could support investor interest in its commercial and pipeline opportunities. Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves
• Neutral Sentiment: Forecasts remain mixed: Zacks lowered estimates for the first quarter of 2027, third and fourth quarters of 2027, full-year 2027 and first quarter of 2028, including a reduction in the FY2027 loss forecast from $0.36 to $0.44 per share. These cuts offset several of the improved estimates.
• Negative Sentiment: Profitability remains ahead, not immediate: Zacks still expects Iovance to report losses through the forecast period, including estimated losses of $0.56 per share in FY2026 and $0.44 in FY2027. Investors therefore remain dependent on revenue growth, commercial execution and clinical progress rather than near-term profits. Zacks Industry Outlook

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc is a clinical‐stage biotechnology company specializing in the development and commercialization of tumor‐infiltrating lymphocyte (TIL) immunotherapies for the treatment of solid tumors. The company's lead product candidate, lifileucel (formerly LN‐144), is an autologous TIL therapy in late‐stage clinical development for patients with advanced melanoma. Iovance's pipeline also includes next‐generation TIL programs such as LN‐145 for cervical and other human papillomavirus (HPV)‐related cancers, as well as exploratory studies in head and neck, non‐small cell lung, gastric and other solid tumor indications.

Iovance's TIL platform harnesses a patient's own immune system by isolating, expanding and reinfusing tumor‐reactive lymphocytes.

Want to see what other hedge funds are holding IOVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source